Soros, Harvard Make Opposite Bets on China Plasma Company: Chart

George Soros and the team that manages Harvard University’s endowment recently made opposite bets on China Biologic Products Inc., a Beijing-based producer of human plasma products. Soros Fund Management LLC raised its stake in the second quarter to make the company its biggest equity holding based in mainland China, while Harvard Management Co. reduced its stake, according to separate regulatory filings in mid-August. Neither fund specified when the transactions were made, though the 52-company Bloomberg World Biotechnology Index has gained about 5 percent since the start of April even as China Biologic shares fell.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.